Cargando…

EE179 Key Drivers of the Economically Justifiable Price of the COVID-19 Vaccine in England

Detalles Bibliográficos
Autores principales:	Aballea, S, Karwala, P, Zerda, I, Toumi, M, Pochopien, M, Borissov, B, Clay, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232740/ http://dx.doi.org/10.1016/j.jval.2022.04.428

Ejemplares similares

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

PIN34 COVID 19 – What Is the Health-Economic Economically Justifiable Price of Lockdown?
por: Gani, R., et al.
Publicado: (2020)

Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom
por: Zeevat, F, et al.
Publicado: (2021)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom
por: Kohli, M., et al.
Publicado: (2023)

Prophylaxis for the Prevention of PJI after TAA: Is It Economically Justifiable?
por: Martinazzi, Brandon J., et al.
Publicado: (2022)

Key drivers for market penetration of biosimilars in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2017)

Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment
por: Qiu, Tingting, et al.
Publicado: (2022)

The Price of Glass Eyes in England
Publicado: (1894)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Health Tract, No. 179: Stammering
Publicado: (1863)

Health Tract, No. 179: Stammering
Publicado: (1865)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

EE99 Economic Burden of COVID-19 in Mexico
por: Frias Gasga, AE, et al.
Publicado: (2022)

EE564 Study on the Value Pricing of COVID-19 Vaccine in China Based on the Evidence of Cost-Effectiveness Analysis
por: Fu, Y., et al.
Publicado: (2023)

Brand Cigarillos: Low Price but High Particulate Matter Levels—Is Their Favorable Taxation in the European Union Justified?
por: Wasel, Julia, et al.
Publicado: (2015)

Measurement of the cross-section for the process $ee \to ee\gamma^{*}\gamma^{*} \to eeX$ at $\sqrt{S_{ee}}$ = 189 GeV
por: Przybycien, M B
Publicado: (2000)

The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?
por: Kaufmann, A F, et al.
Publicado: (1997)

Erratum: memorandum on the PS 179 experiment
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1983)

179 Responsible Conduct of Research for Undergraduates
por: Moses, Jennifer, et al.
Publicado: (2022)

EE98 Health Economic Evaluation of COVID-19 Vaccines: A Systematic Literature Review
por: Li, Y., et al.
Publicado: (2023)

Analysis of the interaction between Zinc finger protein 179 (Znf179) and promyelocytic leukemia zinc finger (Plzf)
por: Lin, Ding-Yen, et al.
Publicado: (2013)

The alpha decay of $^{179}$Hg and $^{178}$Hg
por: Hansen, P G, et al.
Publicado: (1971)

The alpha decay of $^{179}Hg$ and $ ^{178}Hg$
por: Hansen, P G, et al.
Publicado: (1971)

Is Gastrostomy Justifiable?
Publicado: (1909)

EE7 Economic Evaluation of COVID-19 Vaccines: A Targeted Literature Review
por: Addae, A, et al.
Publicado: (2022)

Justified defection is neither justified nor unjustified in indirect reciprocity
por: Yamamoto, Hitoshi, et al.
Publicado: (2020)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Factors influencing the COVID-19 daily deaths' peak across European countries
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England
por: Knock, Edward S., et al.
Publicado: (2021)

Measurement of the cross-section for the process ee --> ee gamma[sup *] gamma[sup *] --> eeX at sqrt(s[sub ee]) = 189--202 GeV
por: Przybycien, M B
Publicado: (2001)

Energy Pricing: Economics and Principles
por: Conkling, Roger L
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mdr6043q5jgigc4cki31ktmlq1